Table 1 Patient and clinical characteristics (N = 169)
Characteristics | BRCA wild-type (N = 122) | BRCA mutation (N = 47) | P |
|---|---|---|---|
Age, median (range), years | 57 (32–77) | 56 (27–76) | 0.610 |
CA-125 level, median (range), U/mL | 1958.7 (94.2.0–21,994.8) | 1711.3 (75.0–23,919.0) | 0.759 |
FIGO stage, n (%) | |||
 III | 56 (45.9%) | 23 (48.9%) | 0.734 |
 IV | 66 (54.4%) | 24 (51.1%) |  |
Grading | |||
 1 | 3 (2.5%) | 0 (0%) | 0.489 |
 2 | 11 (9.0%) | 2 (4.5%) |  |
 3 | 102 (83.6%) | 42 (89.4%) |  |
Not available | 6 (4.9%) | 3 (6.4%) | Â |
Tumor burden assessed by diagnostic laparoscopy* | |||
 PIV 8 | 27 (22.1%) | 3 (6.4%) | 0.097 |
 PIV 10 | 25 (20.5%) | 14 (29.8%) |  |
 PIV 12 | 10 (8.2%) | 4 (8.5%) |  |
 PIV 14 | 5 (4.1%) | 1 (2.1%) |  |
 Not available | 55 (45.1%) | 25 (53.2%) |  |
CRS, n (%) | |||
 1–2 | 79 (64.8%) | 31 (66.0%) | 0.516 |
 3 | 43 (35.2%) | 16 (34.0%) |  |
Residual disease, n (%) | |||
 No | 62 (50.8%) | 18 (38.3%) | 0.344 |
 Any residual | 58 (47.5%) | 28 (59.6%) |  |
 Not available | 2 (1.6%) | 1 (2.1%) |  |
Radical surgery†, n (%) |  |  |  |
 None | 59 (48.4%) | 19 (40.4%) | 0.354 |
 Any radical surgery | 63 (51.6%) | 28 (59.6%) |  |
Surgical complexity score groups‡ | |||
 1–2 (Low/intermediate) | 102 (83.6%) | 37 (78.7%) | 0.457 |
 8 (High) | 20 (16.4%) | 10 (21.3%) |  |
Chemotherapy regimen, n (%) | |||
 Paclitaxel + carboplatin | 91 (74.6%) | 34 (72.3%) | 0.576 |
 Docetaxel + carboplatin | 8 (6.6%) | 6 (12.8%) |  |
 Weekly paclitaxel + carboplatin | 15 (12.3%) | 5 (10.6%) |  |
 Paclitaxel + carboplatin + bevacizumab | 8 (6.6%) | 2 (4.3%) |  |